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Antithymocyte Globulin Antibody Titer 
Congruent With Kidney Transplantation: 
Analysis of Incidence, Outcomes, Cost, and 
Alternative Targets
Sherene Lattimore, BS,1 Nicholas J. Skill, PhD,1 Mary A. Maluccio, MD,1 Holly Elliott, BS,1  
Elizabeth Dobben, MD,1 Asif Shafuddin, MD,1 and William C. Goggins, MD1
Antibody-mediated rejection (AMR) is a significant com-plication after kidney transplantation that carries a 
poor prognosis.1 Approximately 10% of kidney transplant 
patients experience AMR. Of which 30% will experience 
graft loss as a consequence. To prevent AMR, rabbit antithy-
mocyte globulin (rATG) induction immunosuppression 
is widely used to eliminate T helper cells, decrease donor-
specific antigen (DSA) antibody titers, and reduce B-cell dif-
ferentiation to plasma cells.2-4 However, antibodies against 
rATG can negate its therapeutic purpose.5 This is particularly 
important when deliberating follow-up rATG to combat sus-
pected AMR.
The primary objective of this study was to identify the inci-
dence of positive anti-rATG antibody titers in renal transplant 
recipients at the Indiana University Health Transplant pro-
gram between 2004 and 2018. The secondary objective was to 
determine correlating factors, outcomes, and cost associated 
with positive anti-rATG antibody titer. The final objective was 
to investigate immunologic regulators of antibody production 
to identify targets for future investigations directed to reduce/
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Basic Science
Background. Rabbit antithymocyte globulin (rATG) use for immunosuppression induction is widespread but is con-
traindicated by the presence of anti-rATG antibodies. This study reports the incidence of positive anti-rATG antibody titers in 
patients before and after renal transplant and evaluates associated outcomes and costs. In addition, it will correlate CD40L 
and interleukin (IL)-21 with anti-rATG antibody titers. Methods. Clinical and billing records from the Indiana University 
Transplant Laboratory were reviewed for positive versus negative anti-rATG antibody titers, graft survival, and 7-day readmis-
sion costs between 2004 and 2018. Serum from patients with positive and negative rATG antibody titers were quantitated 
for CD40L and IL-21 by enzyme-linked immunosorbent assay. Results. On average, between 2004 and May 2018, 163 
kidney transplants per year were performed. Anti-rATG antibody titers were ordered for 17 patients/year, of which 18.2% 
were positive at 1:100 titer either pre- or post-transplant. Time to graft loss correlated with a positive rATG titer at time of 
readmission. Moreover, second kidney transplant increased the anti-rATG positive rate. A weak correlation was observed 
between anti-rATG titer and recipient age. Seven-day readmission treatment costs were significantly lower in patients with 
positive anti-rATG titer. IL-21 and CD40L were significantly greater in patients with positive anti-rATG titers after transplant 
when compared with negative anti  rATG patients. Conclusions. Positive anti-rATG antibody titer is associated with 
a significant negative impact on outcomes. Monitoring of anti-rATG antibody titer is recommended to optimize treatment 
options in patients, especially in the setting of second transplants. Elucidation of the mechanisms associated with positive 
anti-rATG antibody is required. IL-21 and CD40L are potential targets for future study.
(Transplantation Direct 2019;5: e493; doi: 10.1097/TXD.0000000000000933. Published online 27 September, 2019.)
2 Transplantation DIRECT   ■   2019 www.transplantationdirect.com
prevent positive anti-rATG antibody titer in renal transplant 
recipients.
rATG is a mixture of polyclonal rATGs that interact with 
immune response antigens, adhesion molecules, and cell-traf-
ficking molecules resulting in rapid T-cell and B-cell depletion 
through complement-dependent cell lysis and apoptotic cell 
death in lymphoid tissues.6 rATG is prepared by immunizing 
pathogen-free rabbits with a cell suspension of human thymic 
tissue. After immunization, the serum is harvested and immu-
noglobulins against thymocytes are isolated and purified.7 
Lymphocyte depletion occurs rapidly following the adminis-
tration of rATG, within 2–3 hours and recovers gradually after 
treatment. T-cell counts begin to return toward baseline after 
about 10 days.8 By 3 months, approximately 40% of patients 
recover >50% of the initial lymphocyte counts but disruption 
of subsets and CD4 T cells counts can be long-lasting.9
At Indiana University Hospital renal transplant program, 
anti-rATG antibody titers are performed on patients read-
mitted with suspected acute or chronic renal rejection. The 
purpose is to determine the applicability of repeated rATG 
treatment. While this approach will avoid contraindicated 
treatment, the question of how to prevent positive anti-rATG 
antibody titers and how best to treat patients with positive 
anti-ATG antibody titers remains.
One strategy to prevent positive anti rATG antibody titers 
is to further limit the maturation of B cells to antibody-pro-
ducing plasma cells.10 In renal recipients, B-cell populations 
are significantly reduced by rATG. However, B-cell levels are 
not eliminated entirely and do recover in patients, despite 
maintenance immunosuppression.11 For example, studies 
have shown that renal transplantation long-term outcomes 
are impacted by DSA which elicit AMR through B-cell dif-
ferentiation to plasma cells despite use of rATG.12 Suggesting 
that B-cell disruption is not always successful. Therefore, 
reducing antibody production by reducing the generation of 
antibody-producing plasma cells by a non-rATG protocol 
may be advantageous.
Antibody production is modulated by integrated signals 
from antigen-presenting cells and helper T cells.13 In particular, 
T follicular helper cells play a crucial role in AMR, because 
they help naïve B cells to differentiate into memory B cells and 
alloantibody-producing plasma cells within germinal centers. 
In this way, they contribute to the induction of DSA antibodies, 
which are responsible for the humoral immune response to the 
allograft.12 A literature search focused on the maturation of B 
cells identified CD40L and interleukin (IL)-21 as key. In particu-
lar, studies show CD40L and IL-21 as key signaling molecules 
involved in T follicular helper cell–associated B-cell differentia-
tion (Figure 1).14 Moreover, anti-CD40L antibodies are used to 
prevent AMR in models of xenotransplantation.15 As CD40L 
and IL-21 are important in anti-DSA antibody production, it is 
possible that they are also important in anti-rATG antibodies 
production and are a potential target for intervention.
IL-21 is a member of the IL cytokine family and has pleio-
tropic biological effects on lymphoid and myeloid cells via 
IL-21 receptor on T cells and B cells. It is mainly synthesized 
and secreted by activated CD4(+) T cells and natural killer16 T 
cells. As an immunoregulatory factor, IL-21 and IL-21 recep-
tor play important roles in the development and progression 
of various autoimmune diseases, including lupus erythemato-
sus and osteoarthritis.17,18 Consequently, modulation of IL-21 
synthesis and signaling may be successful to abate solid organ 
rejection.
CD40L (also known as CD154) and its receptor CD40 
belongs to the Tumor Necrosis Factor:Tumor Necrosis Factor 
Receptor family.19 CD40 is expressed on B cells, macrophages, 
and dendritic cells and is important for generation of long-
lived plasma cells and memory B cells.20-22 CD40L is expressed 
by immune cells, endothelial cells, and activated platelets.23-25 
Targeting of CD40L, via the use of statins, has been suggested 
as a treatment of carcinogenesis.26 To examine the potential of 
targeting IL-21 and CD40L for the prevention of renal rejec-
tion in patients with positive anti-rATG antibody titers, we 
quantitated both in serum collected at the time of readmission 
for suspected AMR in patients with either positive or negative 
anti-rATG titer.
MATERIALS AND METHODS
Patient Population
Data and serum samples collected from patients receiv-
ing renal transplants at the Indiana University Health Organ 
Transplant Unit (IUH-OTU) between January 1, 2004, and 
May 31, 2018, were reviewed. The standard of care for renal 
transplant recipients includes collection and storage of serum 
immediately before transplant and perioperative administra-
tion of rabbit antithymocyte immunoglobulin (rATG).
The immunosuppression induction protocol consisted of 3 
equal doses of rATG (total dose = 6 mg/kg) beginning preopera-
tively with standard premedication given immediately before its 
administration: solumedrol (500 [first dose], 250 [second dose], 
and 120 mg [third dose]), acetaminophen (650 mg), and diphen-
hydramine (25 mg). Maintenance immunosuppression was pri-
marily tacrolimus monotherapy, although some early recipients 
did receive a short steroid taper with steroid withdrawal within 3 
months of transplantation. Recipients also received a single dose 
of rituximab between the first and second doses of rATG.27
Suspected Renal Rejection
In patients who presented with symptoms of acute or 
chronic renal rejection (decreased renal function, general dis-
comfort, uneasiness, or ill feeling, pain, or swelling in the area 
FIGURE 1. CD40 ligand regulates IL-21–induced differentiation of 
B cells into either plasma cells or granzyme B-secreting cells. B cells 
that are activated by specific BCR crosslinking associated with CD40L 
negative T helper cells and IL-21 differentiate into GrB-secreting B 
cells (right). In contrast, B cells activated by antigen-specific CD4+ T 
cells that express both IL-21 and CD40 ligand differentiate activated 
B cells into plasma cells (left). BCR, B-cell receptor; GrB, granzyme 
B; IL, interleukin. (Reproduced from Hagn and Jahrsdörfer,14 no 
modifications, open-access license https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC3518509.)
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of the organ, fever, and flu-like symptoms, including chills, 
body aches, nausea, cough, and shortness of breath), serum 
samples were tested for anti-rATG antibody titers (1:100, 
1:500, and 1:1000) and compared with serum samples col-
lected pre-transplant and stored within the IUH transplant 
immunology (TRIM) sample repository.
Database
From IUH TRIM laboratory records, a database of renal 
transplant recipients who had anti-rATG antibody titers quan-
titated at the time of transplant and following readmission 
for suspected rejection between 2004 and 2018 was created 
using Excel. The database included age, gender, date of trans-
plants, patient survival, graft survival, number of transplants, 
lymphocyte populations, rATG antibody titers (at transplant 
and at suspected rejection), and cytomegalovirus (CMV) virus 
status. There was no selection bias, other than the availability 
of clinical follow-up for clinical correlates.
Anti-rATG Enzyme-Linked Immunosorbent Assay
Performed by the TRIM laboratory using an enzyme-linked 
immunosorbent assay (ELISA) assay developed in-house. The 
TRIM laboratory is accredited with the College of American 
Pathologists (CAP #1678922) and CMS Clinical laboratory 
Improvement Amendment certified (CLIA#15D0689426) to per-
form clinical testing. Serum samples are diluted (1:100, 1:500, and 
1:1000) and incubated (quadruplicate) in 96-well plates coated 
with rabbit thymoglobulin for 45 minutes at room temperature. 
After triplicate washing with phosphate buffered saline (PBS), 
antibody binding was revealed with goat anti-human immuno-
globulin G-peroxidase conjugate incubation for 45 minutes at 
room temperature. After triplicate washing with PBS, peroxidase 
substrate was added. After 20 minutes, the reaction was stopped 
with 1N sulphuric acid. Plates were read at 460 nm. Quality con-
trol included known positive, known negative, and plate control 
(no thymoglobulin). Quality control data were recorded in Levey 
Jennings charts. Positive, negative, and plate control limits equal 2 
standard deviations of average from previous 12 months analysis. 
Positive titer determined as absorbance greater than double that 
of plate negative. Positive titer was ≤1:100. There are 4 potential 
resultant categories for comparison based on positive or negative 
anti-rATG antibody titer either before or after transplant. Group 
1: negative pre-transplant and negative post-transplant. Group 
2: negative pre-transplant and positive post-transplant. Group 
3: positive pre-transplant and negative post-transplant. Group 4: 
positive pre-transplant and positive post-transplant.
Markers of Anti-rATG Antibody
To investigate the pathways associated with positive anti-
rATG titer serum samples collected from patients with positive 
and negative anti-rATG antibodies were identified from the data-
base. Based on power analysis following preliminary analysis of 
CD40 ligand (CD40L) and IL-21, 13 patients tested positive 
for anti-rATG antibodies were matched with 13 patients who 
have tested negative. Matching was based on similar age, gen-
der, blood type, and renal transplantation. Thirteen positive and 
negatives patients were matched and underwent CD40 ligand 
and IL-21 ELISA testing from commercially available kits.
CD40 Ligand ELISA
Human CD40L was quantitated in serum samples col-
lected after transplant, at time of suspected rejection using 
commercial ELISA (ThermoFisher, IL). Standards were pre-
pared using the standard concentrate that was reconstituted 
using standard diluent. The stock solution is 2000 pg/mL 
and served as the start of a serial dilution with the following 
concentration serving as the standards: 1000, 500, 250, 125, 
62.5, 31.2, 15.6, and 0 pg/mL served as the blank which is 
just standard diluent. Detection reagents A and B were diluted 
100-fold to their working concentration with assay diluents 
A and B. Wash solution was diluted to a 1× concentration 
from the 30× stock concentration. Samples were prepared at 
the suggested 10-fold dilution in PBS. Samples and standards 
(100 µL) were pipetted into wells, covered with a plate sealer, 
and incubated for 1 hour at 37°C. Liquid was removed from 
the wells and not washed. 100 µL of detection reagent A was 
added to the wells and incubated for 1 hour at 37°C. Solution 
was aspirated from the well and washed with 350 µL of pre-
viously prepared wash solution 3 times. Detection reagent B 
(100 µL) is added to each well and incubated for 30 minutes 
at 37°C. Aspiration/wash process was repeated for a total of 5 
times. Substrate solution (90 µL) was added to each well and 
incubated for 10–20 minutes at 37°C. Fifty microliters of stop 
solution and absorbance were measured at 450 nm.
Interleukin-21 ELISA
Human IL-21 was quantitated in serum samples from 
patients after transplant, at time of suspected rejection using 
commercial ELISA (ThermoFisher, IL). Assay diluent B is 
diluted 5-fold with distilled water before use. Serum samples 
are diluted 40-fold with assay diluent C. Standards are pro-
duced by diluting the standard protein with 400 µL of assay 
diluent C which produced a 50 ng/mL stock solution. Using 
the stock solution, a serial dilution was created 0–8000 pg/
mL. Samples and standards (100 µL) are added to each well 
and incubated at room temperature for 2.5 hours. Solution 
is then discarded and washed with 300 µL 4 times. The pre-
pared 1× detection antibody (100 µL) is added to each well 
and incubated for 1 hour at room temperature. Detection 
antibody solution is discarded and the wells are washed 4 
times. Next, 100 µL of Horse Radish Peroxidase-streptavidin 
is added to each well and incubated for 45 minutes at room 
temperature. Horse Radish Peroxidase-streptavidin solution 
is discarded and plate is washed 4 times. 3,3',5,5'-tetrameth-
ylbenzidine—1 substrate reagent (100 µL) —is added to each 
well and incubated for 30 minutes at room temperature in the 
dark. Finally, 50 µL of stop solution is added to each well and 
absorbance is read at 450 nm.
Statistical Analysis of Database
Cox Proportional Hazards Model
Relationships among the length of time on dialysis, anti-
rATG, and time to rejection were performed. Length of time 
on dialysis and anti-rATG antibody result post-transplant 
were used as explanatory variables. Time until rejection was 
used as the time variable, with rejection being the end event. 
This test used all positive assays for individuals following 
their first transplant who were tested for anti-rATG antibody 
titers and had known dialysis times and times until rejection 
(n = 22). Negative assays meeting those criteria were used dat-
ing back to 2011 (n = 90). Age, recipient immunoglobulin G 
status, number of transplants, and anti-rATG antibody titer 
results following transplant were tested for correlation with 
time to rejection using a Pearson correlation test. Dialysis time 
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was excluded from these tests due to no effect on rejection. 
Second transplants were treated as a separate observation 
from first transplants. All patients in the gathered data with 
complete sets of this information were used (n = 132).
Partial Least Square Regression
Was used to evaluate (1) lymphocyte subtypes before trans-
plant as an explanatory variable for time until graft rejection, 
and (2) lymphocyte subtypes before transplant as an explana-
tory variable for anti-rATG antibodies titer. Pearson correlation 
test was used to examine (1) relationship between time before 
rejection and anti-rATG antibody titer, (2) relationship between 
anti-rATG titer before rATG and at time of rejection, and (3) 
correlation between second transplants and anti-rATG titer.
RESULTS
Data Cohort
Between 2004 and 2018, 2278 patients received kidney 
transplants. Of these, anti-rATG antibody titer quantification 
was ordered for 241 patients (10.5%). Forty-four patients 
had a titer >1:100 (positive) (22.3%). Clinical follow-up and 
outcomes were available for 112 patients, 22 positives and 90 
negatives.
The frequency of anti-rATG assay requests is low because 
it is only ordered/captured in our database when patients pre-
sent to the IUH transplant unit outpatient unit with suspected 
renal rejection. Patients who receive their transplant at IUH 
but follow-up care else were not included.
Anti-rATG Titers in Renal Transplant Recipients 
Presenting With Renal Rejection
Anti-rATG antibody titers were extracted from patient 
records. Recipients were transplanted at Indiana University 
Hospital between January 2004 and May 2018. On average, 
160 renal transplants were performed per year. Anti-rATG 
antibody titer quantification was requested by transplant 
nephrologists and performed by the IUH TRIM laboratory 
on recipients per year. Results were recorded at serum sam-
ples collected at 2 time points: (1) before transplantation, 
and (2) at the time of suspected rejection (post). There were 4 
potential outcomes: (1) 80.4% were negative pre-transplant 
and negative post-transplant (−/−) (2) 0% was negative pre-
transplant and positive post-transplant (−/+), (3) 8.9% were 
positive pre-transplant and positive post-transplant (+/+), and 
(4) 10.7% were positive pre-transplant and negative post-
transplant (+/−).
Patients receiving a second kidney where either (1) 62.5% 
negative pre-transplant and post-transplant or (2) 37.5% 
negative pre-transplant and positive post-transplant. There 
were 4 patients who had anti-rATG antibody titers calculated 
after both renal transplants. Hundred percentage of these 
patients were negative for anti-rATG antibodies after the first 
transplant but 50% were positive after the second transplant. 
There was no evidence of deviation from standard of care 
immunosuppression or noncompliance between the groups at 
first or second transplant.
Outcomes in Renal Transplant Recipients 
Presenting With Renal Rejection
Anti-rATG antibody titer and timing had a significant 
impact on the time to rejection. Recipients who were nega-
tive for anti-rATG antibodies before transplant and at the 
time of presentation (−/−), the time to graft loss was 747 days 
(95% CI, 567-1174). For recipients, positive pre-transplant 
and negative at readmission (+/−), the average time to graft 
loss was 540 days (95% CI, 76-652) (t test +/− versus −/−; 
P < 0.22). For recipients, positive pre-transplant and at time of 
readmission (+/+), the time to graft loss was 216.7 days (95% 
CI, 58-447) (t test +/+ versus −/−; P < 0.04) (Figure 2A).
Risk Factors Associated With Time to Rejection
There was no correlation between length of time on dialysis 
and time to rejection (Hazard Ratio, 1.000, χ2 = 0.001). There 
was also no significant correlation associated with CMV sta-
tus versus time to rejection (coefficient of variance = −0.0093; 
P = 0.29). There was no correlation between white blood cell 
counts and time to rejection (PLS Q2 = −0.059). There was no 
correlation between recipient age and time to rejection (coeffi-
cient of variance = −0.005; P = 0.951). There was no correlation 
between number of transplants and time to rejection (coeffi-
cient of variance = 0.01; P = 0.911). There was a correlation 
FIGURE 2. Graft survival associated with anti-rATG antibody titer. A, Time to graft loss from time of anti-rATG antibody assay was evaluated 
from clinical records for patients who were (1) negative at both pre-transplant and at time of presentation for renal rejection (−/−), (2) positive 
at both time of transplant and at time of presentation for renal rejection (+/+), and (3) positive at time of transplant but negative at time of 
presentation for renal rejection (+/−). Students t test −/− vs +/+; P < 0.05. Students t test (−/−) vs (+/−);P = 0.22. B, Renal graft survival Kaplan-
Meier curve for each group. rATG, rabbit antithymocyte globulin.
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between positive anti-rATG antibody titer and time to rejec-
tion, coefficient of variance (−0.224; P = 0.01) (Figure 2B).
Risk Factors Associated With Positive Anti-rATG 
Antibody Titer
There was no significant correlation between length of time 
on dialysis and positive anti-rATG antibody titer (Hazard 
Ratio = 1.000, χ2 = 0.001). There was a possible correla-
tion between patient age at time of transplant and positive 
anti-rATG antibody titer (coefficient of variance = 0.106; 
P = 0.228). There was no significant correlation between CMV 
status and positive anti-rATG antibody titer (coefficient of 
variance = −0.63; P = 0.47). There was a possible correlation 
between number of transplants and positive anti-rATG anti-
body titer (coefficient of variance = −0.09; P = 0.264).
Positive Anti-rATG Antibody Rate Following Second 
Transplant
Between 1975 and May 2018, 40 patients received 2 renal 
transplants at IUH. First transplants were performed between 
May 1975 and January 2017. Second transplants were per-
formed between May 1981 and March 2018. The average 
time between transplants was 3431 ± 412 days. Following the 
first transplant, 12.5% of patients had anti-rATG antibody 
titers quantified. The anti-rATG antibody-positive rate was 
0%. Following the second transplant, 8 patients had anti-
rATG antibody titers quantified at presentation for suspected 
rejection (20%). Three patients had a positive anti-rATG titer 
at presentation (37.5%). Four patients were in both groups 
(anti-rATG antibody titers were calculated after both first and 
second transplants). The anti-rATG antibody titer positive 
rate was 50% after the second transplant.
Serum IL-21
Serum IL-21 levels were quantitated in renal transplant 
recipients at the time of suspected AMR (N = 26). There were 
2 groups. Group 1: recipients with a negative anti-rATG 
antibody titer before and after transplant (−/−) (N = 13), and 
group 2: recipients with a positive anti-rATG antibody titer 
before and after transplant (+/+) (N = 13). IL-21 was signifi-
cantly greater in patients with positive anti-rATG antibody 
titer (88.5 ± 14.3 ng/mL) when compared with negative anti-
rATG antibody patients (33.8 ± 10.7 ng/mL). Unpaired t test 
negative versus positive, P = 0.002 (Figure 3B).
Serum CD40 Ligand
Serum CD40L levels were quantitated in renal transplant 
recipients at the time of rejection (N = 26). There were 2 
groups. Group 1: recipients with a negative anti-rATG titer 
before and after transplant (−/−) (N = 13), and group 2: recipi-
ents with a positive anti-rATG titer before and after trans-
plant (+/+) (N = 13). Serum CD40L was significantly greater 
in patients with a positive anti-rATG titer (552 ± 76 pg/mL) 
when compared with negative anti-rATG controls (333 ± 54 
pg/mL). Unpaired t test negative versus positive, P = 0.049 
(Figure 3A).
Rejection Treatment Costs
To evaluate the financial burden associated with renal rejec-
tion in the presence of anti-rATG antibodies, 7-day total billable 
charges were extracted from clinical records for patients after 
anti-rATG antibody analysis (N = 13 positive/positive and N = 13 
negative/negative). In patients with a negative anti-rATG anti-
body titer, pre- and post-transplant, the 7-day hospital costs was 
$43,284 ± $14,529 (range $21,130–74,961; Figure 4). In patients 
with a positive anti-rATG antibody titer, before and after trans-
plant, the 7-day cost of treatment was $15,657 ± 8,501 (range 
$3,969–$33,700; Figure 4). There was no significant difference 
in costs between negative pre- and post-transplant patients and 
positive pre-transplant and negative post-transplant patients. 
This is because clinical treatment options are based on the post-
transplant titer. None of the patients lost their kidney within the 
7-day billing period monitored. That was one of the reasons the 
billing period was narrow. Consequently, costs associated with 
graft loss were not captured and therefore not included.
DISCUSSION
rATG is a powerful tool to encourage organ tolerance fol-
lowing kidney transplant. However, the development of anti-
rATG antibodies limits its use in the context of acute and 
chronic renal rejection. Patients with anti-rATG antibodies 
have a significantly reduced graft survival. Moving forward, 
we are motivated to better understand the incidence, risk fac-
tors, and implications of anti-rATG antibody-positive titer to 
better counsels patients, improve patient stratification, and 
propose alternative targets for treatment.
Using clinical records pertaining to patients receiving 
renal transplants at the IUH between 2004 and 2018, we 
FIGURE 3. CD40L and IL-21 are significantly elevated contemporaneous with anti-rATG diagnosis. Serum CD40 ligand and IL-21 were 
quantified using commercially available ELISA-based assays. Levels were significantly increased contemporaneous with anti-rATG titer (t test; 
P = 0.049 and P = 0.002, respectively). ELISA, enzyme-linked immunosorbent assay; IL, interleukin; rATG, rabbit antithymocyte globulin.
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report that the incidence of anti-rATG antibodies in patients, 
whom experience episodes of suspected renal rejection and 
were readmitted to IUH, to be 26%. Moreover, a reduction 
in the time to rejection was strongly associated with positive 
anti-rATG antibody titer. There was a possible correlation 
between age of recipient or number of transplants and posi-
tive anti-rATG antibody titer. In contrast, there was no cor-
relation between anti-rATG antibody titer and either length 
of time on dialysis or CMV status. Moreover, positive anti-
rATG titers were associated with a lower 7-day total billable 
events. This lower cost is due, in part, to the absence of rATG. 
The lack of difference in cost between −/− and +/− patients 
is because only post-transplant titers are reported. Therefore, 
both groups potentially will receive additional rATG. It is not 
possible to provide an accurate percentage of patients with 
positive rATG antibody titers for the entire transplant cohort 
at IUH as many patients who are transplanted at IUH receive 
follow-up care elsewhere. The number of patients receiv-
ing anti-rATG antibody quantitation was low because anti-
rATG antibody titers are only ordered at time of suspected 
rejection and these rates are low. Interestingly, we did not 
observe patients that were negative pre-transplant and posi-
tive post-transplant (−/+). This is potentially an artifact due 
to the low sample size. We did observe patients whom were 
−/+ following liver and lung transplants. Demonstrating that 
rATG positive titers can manifest after solid organ transplant. 
Consequently, additional data are required. If the finding that 
patients with a negative anti-rATG titer pre-transplant do 
not develop anti-rATG antibodies in response to rATG, then 
an argument could be made to screen all kidney transplant 
patients pre-transplant. A negative titer pre-transplant would 
negate the need for qualification at the time of suspected rejec-
tion. Moreover, such a finding would prompt studies into the 
unique characteristics of renal transplant and immunosup-
pression that differentiates it from lung and liver transplants. 
Any suggestion that all patients should receive anti-rATG 
antibody quantification as part of their presurgery work up 
is debatable. The assay is not commercially available and has 
been established in-house at IUH TRIM laboratory. Any deci-
sion would require a cost-benefit analysis, considering the cost 
of the assay and frequency of the event. We do not have access 
to all the financials for the patients and cost of renal rejection/
graft loss and so such an analysis is beyond our expertise. 
The limited financial burden we have is presented to start the 
conversation and promote further studies.
To evaluate potential targets to prevent anti-rATG anti-
bodies, we investigated 2 signaling molecules associated with 
DSA antibody-mediated rejection, IL-21, and CD40L after 
transplant and at the time of suspected rejection in patients 
that were either −/− or +/+. Patients whom were +/− were not 
included. It is anticipated that this group of patients will be 
included in future studies. IL-21 is a cytokine that plays a 
major role in stimulating the differentiation of B cells.14 When 
human B cells are stimulated through the B-cell receptor, 
IL-21 induces minimal proliferation, IgD down-modulation, 
and small numbers of plasma cells.14,28 Importantly, the effects 
of IL-21 on B-cell differentiation are crucially influenced by 
multiple T-cell–derived factors. Previous studies indicate that 
the IL-21–induced differentiation of plasma cells is strongly 
supported by CD4+ T-cell help, which includes CD40L. At the 
same time, CD40L strongly inhibits IL-21–induced granulo-
cyte B expression by B cells. Fully activated CD4+ T cells (ie, 
receiving T cell receptor stimulation and costimulatory sig-
nals) express both IL-21 and CD40L, explaining their robust 
ability to favor the differentiation of plasma cells. In contrast, 
incompletely activated CD4+ T cells (receiving T cell receptor 
stimulation only) express IL-21 but not CD40L, making them 
potent inducers of granulocyte B production by B cells. In 
kidney recipients with a positive anti-rATG antibody titer, cir-
culating IL-21 and CD40L were significantly increased when 
compared with patients with negative anti-rATG antibody 
titer. Consequently, targeting IL-21 and CD40L are potential 
targets to prevent the generation of antibodies to rATG and 
other DSA.
There are numerous reports relating to targeting IL-21 
and CD40L for therapeutic benefit. For example, targeting 
IL-21 for therapy has been suggested to treat Crohn's disease, 
rheumatoid arthritis, and diabetes mellitus.29-31 A review of 
US national library of medicine clinical trials database (www.
clinicaltrials.gov) identified several clinical trials focused on 
the use of recombinant IL-21 to treat several types of can-
cer.32-36 Inversely, there is a clinical trial using a recombinant 
anti-IL-21 monoclonal antibody in healthy subjects with rheu-
matoid arthritis. The study found that single doses (≤25 mg/
kg IV; ≤4 mg/kg SC) were well tolerated and that the accumu-
lation of IL-21–containing complexes suggests neutralization 
of IL-21.37 In a similar manner, there are numerous clinical 
trials focused on the treating of cancer with CD40L38-40 and 
anti-CD40L therapy has been the focus in the prevention of 
renal rejection in nonhuman primates40 and as a potential 
novel treatment for autoimmune diseases.41,42 In particular, 
anti-CD40L antibody lacking an Fc domain has been shown 
to inhibit CD40L-dependent immune responses without 
FIGURE 4. Seven-day hospital costs for treating renal rejection in 
patients with positive and negative anti-rATG antibody titers. Average 
7-day hospital costs for patients with suspected antibody-mediated 
renal rejection postrenal transplant was pooled from billing records for 
patients who had tested positive or negative for anti-rATG at Indiana 
University Health renal transplant program between 2007 and 2018 
(N = 13). Student’s t test, P < 0.01.Chart 1. Anti-rATG antibody titer 
data. rATG, rabbit antithymocyte globulin.
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thrombotic complications and effectively prevents nonhuman 
primate renal allograft rejection.43,44
We are cognizant to the possibility that reduced graft sur-
vival time observed in patients with a positive anti-rATG 
antibody titer is independent of the anti-rATG antibodies. 
For example, reduced survival time could be linked directly to 
the pathobiology associated with increased IL-21 levels. For 
example, studies have shown that increased IL-21 in T cells 
enhances cell cytotoxicity.45 Moreover, IL-21 is also increased 
in other immune-mediated pathologies such as osteoarthri-
tis.17 However, IL-21 and CD40L levels are known to be 
unaffected by standard triple maintenance immunosuppres-
sion (calcineurin inhibitors +  mycophenolate mofetil + ster-
oids) typically used following renal transplant.3 This evidence 
argues that high IL-21 and CD40L are potentially pathogenic 
for B-cell differentiation and antibody production.
At this time, we can only speculate regarding positive rATG 
titer in patients before administration of rATG. As rATG is 
primarily rabbit immunoglobulins, it is possible that patients 
with a positive anti-rATG titer have had previous exposure 
to rabbit immunoglobulins. In the alternative, they could be 
false positives in a similar manner to that seen with thyro-
tropin radioimmune assays.46 Moreover, we are unable to 
categorically explain the observation of patients with positive 
pre-transplant anti-rATG antibody titer but a negative post-
transplant anti-rATG antibody titer. An increase in anti-rATG 
titer following rATG treatment may be related to studies that 
show rATG induces complement-independent apoptosis of 
naive, activated, and plasma B cells.47 Whatever the mecha-
nism associating IL-21 and CD40L to renal graft loss the 
results of this study, in combination with works by others 
suggest that targeting IL-21 or CD40L signaling is a poten-
tial target for exploration to address anti-rATG antibodies in 
renal recipients.
Finally, additional studies are required to better understand 
the link between immune maintenance/protocol and anti-
rATG antibodies titer. It is possible that immunosuppression 
combinations and patient compliance could be important. 
Studies have reported that monotherapy with tacrolimus is 
associated with higher rejection rates compared with 2 drug 
or 3 drug immunosuppression.16 In a similar manner, differ-
ences in immunosuppression may manifest a risk factor for 
rATG induction.
CONCLUSIONS
Anti-rATG antibody-positive titer is associated with 
reduced outcomes for renal transplant recipient. Alternative 
targets to disrupt B-cell maturation pathways, such as IL-21 
and CD40L, are potential areas for future studies.
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